Status:
COMPLETED
Heparin Antibodies in Intensive Care Unit Patients (HAICU)
Lead Sponsor:
The University of Texas Health Science Center, Houston
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Heparin-Induced Thrombocytopenia
Eligibility:
All Genders
18+ years
Brief Summary
Intensive care unit patients have multiple risk factors for venous thromboembolism. Venous thromboembolism leads to significant morbidity and can be fatal. Unfractionated heparin and low molecular wei...
Detailed Description
Venous Thromboembolism (VTE) is common in the intensive care unit (ICU); VTE leads to significant morbidity and is fatal in 30% of undiagnosed pulmonary emboli and 8% when PE is appropriately treated....
Eligibility Criteria
Inclusion
- Adult patients (\> 18 years of age) admitted to the
- Neuro-trauma intensive care unit (NTICU)
- Shock-trauma intensive care unit (STICU) or
- Medical intensive care unit (MICU).
- Completed informed consent process.
Exclusion
- Admitted to ICU for short-term observation or expected hospital length of stay of less than 5 days
- Undergoing or planned plasmaphoresis
Key Trial Info
Start Date :
November 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2006
Estimated Enrollment :
185 Patients enrolled
Trial Details
Trial ID
NCT00283322
Start Date
November 1 2004
End Date
May 1 2006
Last Update
December 6 2007
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Florida Hospital Center for Hemostasis & Thrombosis (Laboratory)
Orlando, Florida, United States, 32804
2
UT-Houston/Memorial Hermann Hospital
Houston, Texas, United States, 77030